Clinical Trial Update: Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy

View source ↗

Summary

A recruiting clinical trial evaluating adjuvant therapy that combines chemotherapy with targeted therapy for intermediate-risk HER2-positive, lymph node-negativ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Shu Wang | Conditions: HER2-positive Breast Cancer | Status: RECRUITING